



Transporters- Beyond DDI

James Tack
Account Operations Manager
jtack@absorption.com

Our Philosophy

We develop innovative research tools to identify and overcome ADMET barriers to development of drugs and devices.

- A Commitment to Science and Service

Classes of Transporter Studies

DDI/Safety

- Emerging Clinical Importance of OCT1 in PK, PD, PgX, and DDIs
- Investigation of Endogenous Biomarkers Applicable to Drug Interactions Involving Transporters Using Animal Models and Metabolomics

Mechanistic/Research

- CNS Delivery of Therapeutic Antibodies
- Role of Intestinal Nutrient Transporters in Drug Absorption
- The Role of Transporters in ADME of Antibody Drug Conjugates
- Lysosomal Transporters Gain Momentum in Research
- Organic Solute Transporter OST α/β : An Overlooked Transporter in Drug-Bile Acid Interactions

Classes of Transporter Studies

DDI / Safety

- De-risk potential enzyme mediated interactions
- Required to exit clinic
- Evaluated for Safety

Considerations:

- Validated Cell Lines (IVIC)
- Rigorous Analytical Methods
- Adherence to Relevant Guidance


Mechanistic/Research

- Disposition of Therapeutic Agents
- De-risking Site Specific Interactions
- Evaluated for Efficacy

Allowances:

- Novel Cell Lines
- Screening Analytical Methods
- Adherence to Scientific Method

Research Transporter- OATP2A1-HEK239



- Expressed in the Eye, Lung, and in Pancreatic Cancer
- Involved in the intraocular disposition of Latanoprost
- Potential Target for Disposition of Chemotherapeutic Agents

Our Philosophy

We develop innovative research tools to identify and overcome ADMET barriers to development of drugs and devices.

- A Commitment to Science and Service